Derbyshire Medicines Management and Clinical Policies
RED: Monotherapy for the treatment of adults with relapsed and refractory multiple myeloma, who have received ≥3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy
DNP: NICE TA869 - Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (Terminated appraisal) (Decision date - March 2023)
